Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Accumulated Expenses (2016 - 2025)

Marimed (MRMD) has disclosed Accumulated Expenses for 13 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 114.41% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, up 114.41% year-over-year, with the annual reading at $9.5 million for FY2025, 114.41% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.5 million at Marimed, up from $9.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $11.1 million in Q3 2021, with the low at $1.7 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $5.4 million, with a median of $4.6 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses surged 256.59% in 2021, then plummeted 70.57% in 2022.
  • Over 5 years, Accumulated Expenses stood at $3.1 million in 2021, then decreased by 1.84% to $3.1 million in 2022, then grew by 14.82% to $3.5 million in 2023, then rose by 24.96% to $4.4 million in 2024, then soared by 114.41% to $9.5 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $9.5 million, $9.0 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.